Autonomic dysfunction in neuromyelitis optica spectrum disorder and multiple sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511809798587

Enrollment

100

Registered

2025-11-20

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases

Interventions

autonomic symptoms assessment of Multiple Sclerosis group

Objective autonomic function testing of Neuromyelitis Optica Spectrum Disorder group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Adult patients , both sexes. • Confirmed diagnosis of NMOSD according to the 2015 International Consensus Criteria • Confirmed diagnosis of RRMS according to the 2024 McDonald diagnostic criteria

Exclusion criteria

Exclusion criteria: • Comorbidities affecting autonomic function (e.g., diabetes, Parkinsonism) • Medications known to interfere with autonomic testing • Cognitive impairment precluding questionnaire completion

Design outcomes

Primary

Measure	Time frame
Prevalence and pattern of autonomic dysfunction in NMOSD vs MS	—

Secondary

Measure	Time frame
Correlations with disability, MRI findings, fatigue, and quality of life.	—

Countries

Egypt

Contacts

Public ContactMohamed Moshref

residant doctor at neurology

Mohamed.17289897@med.aun.edu.eg+201068960922

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026